Nimotuzumab

CAS No. 828933-51-3

Nimotuzumab( —— )

Catalog No. M28966 CAS No. 828933-51-3

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1017 In Stock
10MG 1359 In Stock
25MG 2024 In Stock
50MG 2688 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nimotuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
  • Description
    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    828933-51-3
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-1400.
molnova catalog
related products
  • Alflutinib methanesu...

    Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.

  • CGP77675

    CGP77675 is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.

  • Tyrphostin A25

    Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.3 μM for GPR35.